Skip to content

PTHS PTHS Debt-to-assets

Debt-to-assets at other companies

Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
0.1×0.0×
Scilex Holding Company logo
Scilex Holding CompanySCLX
0.3×-0.2×
Journey Medical Corporation logo
Journey Medical CorporationDERM
0.3×0.0×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-0.4×
Opko Health logo
Opko HealthOPK
0.0×
Theravance Biopharma logo
Theravance BiopharmaTBPH
0.1×-0.1×

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Calculated from PTHS’s reported figures.

Based on the most recent quarter.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's debt-to-assets?
PTHS (PTHS) reported debt-to-assets of 0.2× in Q1 2026.
What is the long-term trend for PTHS's debt-to-assets?
Over 2 years (2022 to 2025), PTHS's debt-to-assets has grown at a -94.3% compound annual growth rate (CAGR), from 7.9× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.